135 related articles for article (PubMed ID: 10155594)
1. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer.
Drummond M; Davies L
Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.
Souêtre E; Qing W
Pharmacoeconomics; 1994; 6 Suppl 2():36-43. PubMed ID: 10172484
[TBL] [Abstract][Full Text] [Related]
3. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of lenograstim (glycosylated rHuG-CSF) in the treatment of inflammatory breast cancer for Germany and Italy.
Mapelli V; Graf vond der Schulenburg JM; Laaser U; Allhoff PG; Rossi F
Pharmacoeconomics; 1994; 6 Suppl 2():27-35. PubMed ID: 10155593
[TBL] [Abstract][Full Text] [Related]
5. Overview of the lenograstim pharmacoeconomics programme.
Oster G; Menzin J; Richard D; Cour-Chabernaud V
Pharmacoeconomics; 1994; 6 Suppl 2():9-17. PubMed ID: 10155596
[TBL] [Abstract][Full Text] [Related]
6. Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication.
Brice P; Godin S; Libert O; Marolleau JP; Makki J; Extra JM; Faure P; Gisselbrecht C
Pharmacoeconomics; 1995 Mar; 7(3):238-41. PubMed ID: 10155313
[TBL] [Abstract][Full Text] [Related]
7. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study.
Gatzemeier U; Kleisbauer JP; Drings P; Kaukel E; Samaras N; Melo MJ; Cardenal F; Robinet G; Snijder RJ; von Pawel J; Palisses R
Am J Clin Oncol; 2000 Aug; 23(4):393-400. PubMed ID: 10955871
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic evaluation of lenograstim. Conclusions and future directions.
Menzin J; Oster G; Cour-Chabernaud V; Richard D
Pharmacoeconomics; 1994; 6 Suppl 2():53-60. PubMed ID: 10155595
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM).
Takagi T; Sawamura M; Sezaki T; Kashimura M; Tsuchiya J; Hotta T; Ogawa N; Hirashima K
Support Care Cancer; 2001 Jul; 9(5):397-9. PubMed ID: 11497396
[TBL] [Abstract][Full Text] [Related]
10. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
Hanauske AR; Korfel A; Perker M; Heinrich B; Schwab G; Graf M; Depenbrock H; Höffken G; Kreuser ED; Thiel E; Zwingers T; Berdel WE
Oncology; 1997; 54(5):363-70. PubMed ID: 9260596
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
[TBL] [Abstract][Full Text] [Related]
12. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
Dunn CJ; Goa KL
Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
Calhoun EA; Schumock GT; McKoy JM; Pickard S; Fitzner KA; Heckinger EA; Powell EF; McCaffrey KR; Bennett CL
Pharmacoeconomics; 2005; 23(8):767-75. PubMed ID: 16097839
[TBL] [Abstract][Full Text] [Related]
14. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
[TBL] [Abstract][Full Text] [Related]
15. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
Hara T; Tsurumi H; Kasahara S; Kanemura N; Yoshikawa T; Goto N; Kojima Y; Yamada T; Sawada M; Takahashi T; Oyama M; Tomita E; Moriwaki H
Int J Hematol; 2005 Dec; 82(5):430-6. PubMed ID: 16533747
[TBL] [Abstract][Full Text] [Related]
16. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
17. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
Thatcher N; Girling DJ; Hopwood P; Sambrook RJ; Qian W; Stephens RJ
J Clin Oncol; 2000 Jan; 18(2):395-404. PubMed ID: 10637255
[TBL] [Abstract][Full Text] [Related]
18. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
19. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
Glaspy JA; Bleecker G; Crawford J; Stoller R; Strauss M
Eur J Cancer; 1993; 29A Suppl 7():S23-30. PubMed ID: 7508727
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial.
Bojke L; Sculpher M; Stephens R; Qian W; Thatcher N; Girling D
Pharmacoeconomics; 2006; 24(5):443-52. PubMed ID: 16706570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]